Skip to main content

Table 1 Clinical characteristics of patients.

From: Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma

Variables HCC Cohort
(N = 47)
Nontumoral HCC cohort
(N = 44)
Tumor HCC cohort
(N = 43)
Control liver cohort (metastatic liver tumors, N = 8)
Age 66.5 ± 7.8 66.4 ± 7.9 66.5 ± 7.9 60.0 ± 13.5
Gender     
   Male 35 (74.4%) 32 (72.7%) 32 (74.4%) 4 (50.0%)
   Female 12 (25.5%) 12 (27.3%) 11 (25.6%) 4 (50.0%)
Viral infection status     
   HBV infection - - - -
   HCV infection + + + -
Liver resection procedure     
   Lobular/extended lobular 5 5 5 N/A
   Segmental/partial 42 39 38  
Platelet count (104/μl) 12.9 ± 4.3 13.0 ± 4.2 12.8 ± 4.2 19.3+3.6*
Alanine aminotransferase (IU/l) 51.0 ± 31.7 51.0 ± 32.0 51.7 ± 33.1 19.7+7.7*
Total bilirubin (mg/dl) 0.80 ± 0.34 0.76 ± 0.30 0.80 ± 0.35 0.85+0.37
Prothrombin time (%) 78.3 ± 13.1 78.3 ± 12.9 78.1 ± 13.3 91.1+14.5
Indocyanine green (%) 18.4 ± 8.3 18.5 ± 8.3 18.3 ± 8.4 11.0+5.3
α-Fetoprotein (ng/ml) 319 ± 924 339 ± 952 345 ± 962 N/A
Tumor diameter (cm) 2.90 ± 1.30 2.97 ± 1.35 2.95 ± 1.37 N/A
Number of tumors 1.30 ± 0.50 1.32 ± 0.52 1.30 ± 0.51 N/A
Portal vein invasion     
   Present 5 (10.6%) 5 (11.4%) 5 (11.6%) N/A
   Absent 42 (89.4%) 39 (88.6%) 38 (88.4%) N/A
Tumor stage     
   I 9 (19.1%) 9 (20.5%) 8 (18.6%) N/A
   II 25 (53.2%) 23 (52.3%) 24 (55.8%) N/A
   III 12 (25.5%) 11 (25.0%) 10 (23.3%) N/A
   IV 1 (2.1%) 1 (2.3%) 1 (2.3%) N/A
Tumor differentiation     
   Well differentiated 8 (17.0%) 8 (18.2%) 6 (14.0%) N/A
   Moderately differentiated 31 (66.0%) 28 (63.6%) 29 (67.4%) N/A
   Poorly differentiated 8 (17.0%) 8 (18.2%) 8 (18.6%) N/A
Fibrosis score     
   F0 0 (0%) 0 (0%) 0 (0%) 8 (100%)*
   F1 3 (6.4%) 3 (6.8%) 3 (7.0%) 0 (0%)
   F2 6 (12.8%) 5 (11.4%) 6 (14.0%) 0 (0%)
   F3 14 (29.8%) 14 (31.8%) 12 (27.9%) 0 (0%)
   F4 24 (51.1%) 22 (50.0%) 22 (51.2%) 0 (0%)
  1. Data shown are mean ± standard deviation. N/A, data is not available. Asterisk(*) denotes statistical difference from other groups (ANOVA, p < 0.05).